The expanding role of immunotherapy
- PMID: 28231560
- DOI: 10.1016/j.ctrv.2017.01.008
The expanding role of immunotherapy
Abstract
The use of agents able to modulate the immune system to induce or potentiate its anti-tumour activity is not a new strategy in oncology. However, the development of new agents such as immune checkpoint inhibitors has achieved unprecedented efficacy results in a wide variety of tumours, dramatically changing the landscape of cancer treatment in recent years. Ipilimumab, nivolumab, pembrolizumab or atezolizumab are now standard of care options in several malignancies and new indications are being approved on a regular basis in different tumours. Moreover, there are many other novel immunotherapy strategies that are currently being assessed in clinical trials. Agonists of co-stimulatory signals, adoptive cell therapies, vaccines, virotherapy and others have raised interest as therapeutic options against cancer. In addition, many of these novel approaches are being developed both in monotherapy and as part of combinatory regimes in order to synergize their activity. The results from those studies will help to define the expanding role of immunotherapy in cancer treatment in a forthcoming future.
Keywords: Cell therapy; Checkpoint inhibitors; Co-stimulatory agonists; Combination; Vaccines; Virus.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Similar articles
-
Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.Clin Adv Hematol Oncol. 2016 Nov;14(11):922-933. Clin Adv Hematol Oncol. 2016. PMID: 27930644 Review.
-
Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.Drugs. 2017 Jul;77(10):1077-1089. doi: 10.1007/s40265-017-0748-7. Drugs. 2017. PMID: 28493171 Review.
-
Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.Clin Cancer Res. 2015 Dec 15;21(24):5543-51. doi: 10.1158/1078-0432.CCR-14-2009. Epub 2015 Jul 17. Clin Cancer Res. 2015. PMID: 26187615 Free PMC article.
-
Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.Semin Oncol. 2015 Oct;42 Suppl 2:S11-8. doi: 10.1053/j.seminoncol.2015.09.019. Epub 2015 Sep 11. Semin Oncol. 2015. PMID: 26477470 Review.
-
Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.Pharmacotherapy. 2015 Oct;35(10):963-76. doi: 10.1002/phar.1643. Pharmacotherapy. 2015. PMID: 26497482 Review.
Cited by
-
Bioactive Nanoparticles for Cancer Immunotherapy.Int J Mol Sci. 2018 Dec 4;19(12):3877. doi: 10.3390/ijms19123877. Int J Mol Sci. 2018. PMID: 30518139 Free PMC article. Review.
-
[Personalized treatment of cholangiocellular carcinoma (CCA)].Internist (Berl). 2020 Feb;61(2):170-174. doi: 10.1007/s00108-019-00723-w. Internist (Berl). 2020. PMID: 31938815 Review. German.
-
Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study.J Immunother Cancer. 2020 Jun;8(1):e000367. doi: 10.1136/jitc-2019-000367. J Immunother Cancer. 2020. PMID: 32487569 Free PMC article. Clinical Trial.
-
Dendritic Cell Vaccines for Cancer Immunotherapy: The Role of Human Conventional Type 1 Dendritic Cells.Pharmaceutics. 2020 Feb 15;12(2):158. doi: 10.3390/pharmaceutics12020158. Pharmaceutics. 2020. PMID: 32075343 Free PMC article. Review.
-
Successful mycophenolate mofetil treatment of a patient with severe steroid-refractory hepatitis evoked by nivolumab plus ipilimumab treatment for relapsed bladder cancer.Clin Case Rep. 2020 Dec 4;9(2):654-659. doi: 10.1002/ccr3.3597. eCollection 2021 Feb. Clin Case Rep. 2020. PMID: 33598220 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials